Four patients died. The clinical trials froze overnight. Yet across elite rheumatology wards, desperate patients still want in.
They are refusing to walk away. Systemic lupus erythematosus, or SLE, attacks joints, kidneys, hearts, and lungs, leaving patients crippled by agony and organ damage. Current treatments—steroids, hydroxychloroquine, and immunosuppressive biologics—frequently fail. Between 10% and 15% of people diagnosed with lupus die prematurely.
For those stranded at the edge of medical science, an experimental cell therapy originally built for terminal blood cancers offers an alluring escape: total remission.
“I have patients that are literally waiting to get in,” said Dr. Anca Askanase, chief of rheumatology at the Hospital for Special Surgery in New York, who has enrolled candidates in trials sponsored by Bristol Myers Squibb.
My mouth sores were rampant. I was struggling to eat. I was struggling to drink. I was just very, very miserable... I had reached the end of the line with treatments.” >
Brittan Kopittke, Lupus Patient and UNC Patient Counselor
Brittan Kopittke received her lupus diagnosis at 22. In the United States alone, the disorder strikes roughly 300,000 people, typically surfacing between ages 15 and 44. In India, approximately 1 in 1,000 individuals battle the condition annually.
What began as a mild chest rash quickly devastated Kopittke's body. Joint pain locked her limbs. Exhaustion crushed her daily routine. Standard steroid courses failed, as did hydroxychloroquine, an antimalarial drug meant to suppress rogue antibodies.
The disease marched inward, hammering her heart, lungs, and kidneys. By June 2024, Kopittke entered a CAR-T clinical trial at UNC-Chapel Hill.
The therapy engineers the patient's own immune system. Clinicians harvest blood cells called T cells, modify them in a lab to seek out and wipe out malfunctioned antibody-producing B cells, and infuse them back into the bloodstream. The biological shock can be severe.
Kopittke developed cytokine release syndrome, triggering massive whole-body inflammation. Then came ICANS—immune effector cell-associated neurotoxicity syndrome—a high-grade neurological crash that left her unresponsive for three days.
She woke up. Today, two years later, she remains in deep remission without maintenance drugs.
“I do say that I would do this again,” said Kopittke, who now counsels prospective patients at the University of North Carolina.
| CAR-T Trial & Disease Indicators | Clinical Metric / Status |
|---|---|
| Typical Onset Age for SLE | 15 to 44 years |
| Premature Mortality Rate in Lupus | 10% to 15% |
| Estimated Incidence in India | Approximately 1 in 1,000 annually |
| Active CAR-T Autoimmune Trials | ~150 worldwide |
| Recent Trial Fatalities | 4 (3 Novartis, 1 Bristol Myers Squibb) |
| Bristol Myers Projected Resume Year | 2027 |
The medical community's optimism traces back to 2022, when Dr. Georg Schett of the University of Erlangen-Nuremberg published landmark findings showing drug-free remission in lupus patients treated with CAR-T.
Then safety sirens sounded.
In late August, Swiss pharmaceutical giant Novartis suspended eight trials evaluating its rap-cel CAR-T therapy across autoimmune and neurological indications. Three patients died from a rare, severe hyperinflammatory reaction known as IEC-HS (immune effector cell-associated hemophagocytic lymphohistiocytosis).
Novartis confirmed it is reviewing the deaths alongside independent academic specialists, pledging to release clinical findings once investigators determine the biological trigger.
Bristol Myers Squibb also paused trial enrollment after dangerous inflammatory events surfaced. On October 23, the company confirmed the death of a multiple sclerosis patient in one study. While company representatives stated they have isolated the safety issue, clinical restarts will remain on hold until 2027.
Despite the safety freeze, pharmaceutical investment continues unabated. Drug developers including Johnson & Johnson and Gilead are expanding approved cancer platforms into systemic autoimmune disorders.
Roughly 150 clinical trials are exploring CAR-T platforms for lupus, alongside studies targeting myositis, scleroderma, myasthenia gravis, stiff-person syndrome, and multiple sclerosis.
“There’s billions and billions of dollars pouring into this space,” said Dr. P.J. Utz, an autoimmunity researcher at Stanford Medicine.
For patients who have exhausted traditional rheumatology pipelines, the calculation remains unchanged. The lethal risks of experimental cellular reprogramming compete against the certainty of organ failure. Regulatory authorities and trial safety boards will spend the coming months reviewing toxicity thresholds before deciding whether the next wave of patients gets access.